ER-100 Human Trial Explores Epigenetic Reprogramming to Reverse Cellular Aging
The ER-100 human trial is investigating whether epigenetic reprogramming can reverse cellular aging, specifically in damaged retinal neurons. This trial, based on the work of molecular biologists David Sinclair and Yuancheng Lu, uses transcription factors OCT4, SOX2, and KLF4, collectively known as OSK, to attempt to restore youthful gene activity patterns. The trial is in its early stages, focusing on safety rather than proving the reversal of human aging. The research builds on previous animal studies that showed regeneration of optic nerves and improved visual function in aged mice. The trial involves participants with serious optic-nerve diseases, aiming to determine if partial reprogramming can restore function in damaged neurons.